Stem Cell Source in a Treatment Claim: What Was Actually Studied

By the Regenerative Evidence Guide Team

Stem Cell Source in a Treatment Claim: The Short Answer

By Regenerative Evidence Guide Editorial Team. Updated September 26, 2026.

The source of a stem cell product is where the cells came from: your own body, a donor, cord blood, fat, amniotic fluid, or another tissue. A treatment claim only means something if it shows that this same source, prepared the same way, was studied in people for this same condition. If any of that is missing, the claim has an evidence gap.

Imagine you see an ad for a knee injection made from “fat-derived stem cells,” with a page of happy stories. The ad names a cell source. It does not say whether that source was tested in people, or how the cells were handled before the injection. This guide helps you fill in those blanks, or spot that they can’t be filled in.

Safety First: When to Get Medical Help

If you have severe pain, fever, spreading redness, vision changes, sudden weakness, or trouble breathing after any injection or procedure, contact your own clinician right away or call local emergency services. Do not wait to ask the provider who did the procedure.

The FDA lists serious harms tied to unapproved products, including blindness, tumor formation, neurological events, and bacterial infections, some of them life-threatening blood infections.

Stage 1: Name the Cell Source

“Stem cell” is a broad label. Two products with that label can start from very different material. The FDA’s consumer page names several sources behind products it says are unapproved, including:

Stromal vascular fraction, which is a mix of cells taken from fat
Umbilical cord blood and cord blood stem cells
Amniotic fluid
Wharton’s jelly, a tissue from the umbilical cord
Exosomes, which are tiny particles released by cells

Ask two plain questions. Which tissue did the cells come from? Were they your own cells or a donor’s? “Stem cells” with no source named is not an answer.

The source also decides which studies count. A study of one kind of cell tells you little about a different kind, even if both are called stem cells.

Stage 2: Ask What Processing Happened

Processing means everything done to the cells between collection and use. The FDA warns that processing (preparing the product) can bring risks such as cross-contamination with bacteria, viruses, or mold.

The FDA also has a formal idea called minimal manipulation. For cells, it means processing that “does not alter the relevant biological characteristics of cells or tissues.” In its guidance, steps such as cutting, culturing, enzymatic digestion, decellularization, and storage all factor into that judgment. Deciding whether a product meets this standard is the FDA’s job, not the reader’s or the provider’s marketing. What you can do is ask which steps were used, and whether the product studied went through the same steps as the product being offered.

Warning Boundaries: Where a Claim Stops Being Evidence

The source changed. The study used one tissue, and the offer uses another.
The processing changed. The study used a lab-prepared product, and the offer is prepared in a clinic.
The condition changed. The study looked at one problem, and the ad promises help for many.
“Human data” is vague. Human data means results from studies in people. Results only from lab dishes or animals are not human data. Stories and testimonials are not a study.
No trial is involved. The FDA says these products need an Investigational New Drug application (IND) to be legally given, and FDA oversight in a clinical trial before approval. It also says that if you are being charged for these products or offered them outside of a clinical trial, you are likely being deceived.

On approval, the FDA page says the only approved stem cell product type it describes is blood-forming stem cells from umbilical cord blood, approved only for blood disorders. Approval is required before these products are marketed to consumers.

Cell-Source Identity Card

Fill this in for any claim you are checking. Write “not stated” for anything you cannot find in writing. Do not fill a blank with a guess.

Source tissue: Where did the cells come from (fat, bone marrow, cord blood, amniotic fluid, other)?
Donor: Your own cells or someone else’s?
Processing steps: What was done to the cells before use, and where?
Exact product: What is it called, and what is being injected or given?
Condition claimed: Which condition does the claim say it helps?
Human study: Is there a study in people that used this same source, processing, and condition? Where is it registered?
FDA status: Is it approved, or offered only inside a clinical trial?

The FDA page cited in this guide is the reference for line 7 and for the risks above. It does not give a list of questions to ask, so the card is our own framing of its points. For line 6, the trial registry ClinicalTrials.gov publishes a page called How to Read Study Results. When you find a registered study, compare what the record describes with lines 1 through 5 of your card. For more on this topic, see our page on checking FDA status and trial registration for stem cell treatment claims.

Decision Path: What to Do Next

If any line on the card says “not stated,” ask the provider to answer that line in writing. Note whether you get a clear answer.
If the lines are filled in but the study’s source, processing, or condition does not match the offer, treat the study as not covering this offer.
If the product is offered outside a clinical trial and you are being asked to pay, the FDA’s own warning applies. Pause and review the FDA page before deciding anything.
If the product is offered only inside a registered trial, read the trial’s record and ask the study team, not a salesperson, what participants are told about risks.
If the treatment is in another country, read our questions to ask about unproven stem cell claims and travel before you book anything.

Bring your finished card to your own doctor. They know your health history, and this guide does not.

What This Guide Does Not Cover

This guide does not judge any specific product or provider, and it cannot say whether a particular treatment will work or is safe for you. The FDA page cited here was last updated April 8, 2024, so check it for newer changes. We did not draw conclusions from the ClinicalTrials.gov page beyond pointing you to it.

Sources and Editorial Independence

Primary source: FDA, Important Patient and Consumer Information About Regenerative Medicine Therapies. Also used: FDA, Minimal Manipulation and Homologous Use for the definition of minimal manipulation. Reading aid: ClinicalTrials.gov, How to Read Study Results.

Regenerative Evidence Guide is an independent educational publication. It is not connected to any former academy, faculty, conference, or clinical program that used this domain, and it offers no treatment, training, or credentials.

Educational disclaimer: This article is general information, not medical advice. It does not diagnose, recommend treatment, or replace a conversation with your own licensed clinician.